Fatal Allograft Rejection and Cardiac Allograft Vasculopathy After Treatment With Pembrolizumab for Metastatic Melanoma in a Heart Transplant Recipient: A Case Report.

[1]  Lisa E. Vaughan,et al.  Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single‐center analysis , 2020, Cancer.

[2]  N. Zeitouni,et al.  Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. , 2020, Journal of the American Academy of Dermatology.

[3]  M. Mehra,et al.  Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  A. Shinagare,et al.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. , 2020, The oncologist.

[5]  D. Cejka,et al.  Use of Ipilimumab and Pembrolizumab in Metastatic Melanoma in a Combined Heart and Kidney Transplant Recipient: A Case Report. , 2020, Transplantation proceedings.

[6]  M. Suarez‐Almazor,et al.  Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[7]  A. Salama,et al.  Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations , 2018, Melanoma management.

[8]  J. Mazières,et al.  Acute interstitial nephritis related to immune checkpoint inhibitors , 2016, British Journal of Cancer.

[9]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[10]  G. Linette,et al.  Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  J. Taube,et al.  Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. , 2016, The New England journal of medicine.

[12]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[13]  A. Sharpe,et al.  Essential Role of PDL1 Expression on Nonhematopoietic Donor Cells in Acquired Tolerance to Vascularized Cardiac Allografts , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[15]  G. Sica,et al.  Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report , 2016, Cancer Immunology, Immunotherapy.